Consensus is for FY23 revenue $437.26M. Sees FY23 non-GAAP adjusted EBITDA ($25M-($28M) compared to previous guidance of ($5M)-($10M) and a non-GAAP adjusted EBITDA of ($23.8M) in 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVRO:
- Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
- NVRO Upcoming Earnings Report: What to Expect?
- Nevro price target lowered to $27 from $30 at Truist
- Nevro initiated with a Neutral rating, $26 target at Baird
- Nevro initiated with a Neutral at Baird